leadf
logo-loader
viewOkyo Pharma Limited

OKYO Pharma files patent application for Chemerin to treat COVID-19 and ARDS

OKYO Pharma (LON:OKYO) CEO Gary Jacob speaks to Proactive's Andrew Scott following the news it's submitted a patent application for the potential use of its molecule chemerin for the treatment of symptoms associated with COVID-19 and acute respiratory distress syndrome (ARDS).

The project will be spearheaded by Dr. Napoleone Ferrara, a member of OKYO’s scientific advisory board, who invented the blockbuster drug Avastin®.

Quick facts: Okyo Pharma Limited

Price: 8.177 GBX

LSE:OKYO
Market: LSE
Market Cap: £55.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Okyo Pharma Limited named herein, including the promotion by the Company of Okyo Pharma Limited in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: Airline makers and travel firms fly after Boris reveals road...

FTSE 100 rose gently as investors digested Boris Johnson’s roadmap to recovery from Covid-19. London’s blue-chip index rose by 11 to 6,623, suggesting most of the well-leaked plan was already priced in. British Airways owner IAG, aeroengine maker Rolls-Royce and aeroengineer Melrose were the...

1 week, 6 days ago

2 min read